Regeneron Pharmaceuticals, Inc. (REGN) vs Vertex Pharmaceuticals Incorporated (VRTX)

Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated are both Biotechnology companies. Vertex Pharmaceuticals Incorporated is the larger, with a market value of $132.3B against $81.3B — 1.6× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 18.8× against 30.4×. Vertex Pharmaceuticals Incorporated grew revenue faster over the last twelve months: 10.2% against 9.29%. Vertex Pharmaceuticals Incorporated has the higher net margin (35.0% vs 27.9%) and the higher return on invested capital (24.1% vs 9.34%). Across the 22 metrics below, Vertex Pharmaceuticals Incorporated leads on 13 and Regeneron Pharmaceuticals, Inc. on 9.

Valuation

Metric REGN VRTX Biotechnology median
P/E 18.80 30.36 7.88
P/S 5.21 10.61 11.47
P/B 2.55 6.59 2.52
Price to free cash flow 22.66 35.17 21.16
EV/EBITDA 17.32 25.17 0.74
EV/Sales 4.87 10.00 10.73
Earnings yield 5.32% 3.29% (28.84%)
Free cash flow yield 4.41% 2.84% (23.03%)

Profitability

Metric REGN VRTX Biotechnology median
Gross margin 84.86% 86.00% 65.16%
Operating margin 24.74% 37.95% 0.00%
Net margin 27.86% 35.00% 0.00%
Free cash flow margin 23.01% 30.16% 0.00%
Return on equity 14.04% 23.54% (57.72%)
Return on assets 10.83% 17.12% (49.22%)
Return on invested capital 9.34% 24.09% 0.00%

Growth

Metric REGN VRTX Biotechnology median
Revenue growth (TTM) 9.29% 10.23% 5.64%
EPS growth (last fiscal year) 8.19% 836.54% —
Revenue growth, 5-year CAGR 11.04% 14.10% 8.40%
Net income growth, 5-year CAGR 5.10% 7.83% 0.00%

Health

Metric REGN VRTX Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 3.34 3.19 4.73
Net debt to EBITDA (1.43) (1.51) 0.96

Dividend

Metric REGN VRTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric REGN VRTX Biotechnology median
Market cap 81.34b 132.32b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack